Pancreatic ductal adenocarcinoma (PDAC) is the most common, highly aggressive, and challenging to treat pancreatic cancer . It is often diagnosed very late – only after it has become advanced or metastatic. Only about 10% of the patients survive five years, and those with newly diagnosed metastatic PDAC live for less than a year even with optimal chemotherapy.
Surgery is another treatment modality for PDAC. At the American Society of Oncology (ASCO) 2022 meeting, researchers have reported the benefit of combining chemotherapy with immunotherapy in resistant pancreatic cancers and identified novel targets for chemoimmunotherapy. ##Reference## Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial, Nature Medicine (2022).## Would you recommend chemoimmunotherapy in…
